These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 21779443)
1. The genomics of lung adenocarcinoma: opportunities for targeted therapies. Greulich H Genes Cancer; 2010 Dec; 1(12):1200-10. PubMed ID: 21779443 [TBL] [Abstract][Full Text] [Related]
2. Mutation Profile of Resected Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465 [TBL] [Abstract][Full Text] [Related]
3. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study. Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066 [TBL] [Abstract][Full Text] [Related]
4. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing. Shajani-Yi Z; de Abreu FB; Peterson JD; Tsongalis GJ Neoplasia; 2018 Mar; 20(3):256-262. PubMed ID: 29454261 [TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220 [TBL] [Abstract][Full Text] [Related]
6. Mutation profile of non-small cell lung cancer revealed by next generation sequencing. Chang YS; Tu SJ; Chen YC; Liu TY; Lee YT; Yen JC; Fang HY; Chang JG Respir Res; 2021 Jan; 22(1):3. PubMed ID: 33407425 [TBL] [Abstract][Full Text] [Related]
7. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients. Fathi Z; Mousavi SAJ; Roudi R; Ghazi F PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458 [TBL] [Abstract][Full Text] [Related]
8. IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples. Hintzsche J; Kim J; Yadav V; Amato C; Robinson SE; Seelenfreund E; Shellman Y; Wisell J; Applegate A; McCarter M; Box N; Tentler J; De S; Robinson WA; Tan AC J Am Med Inform Assoc; 2016 Jul; 23(4):721-30. PubMed ID: 27026619 [TBL] [Abstract][Full Text] [Related]
9. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA]. Pécuchet N; Legras A; Laurent-Puig P; Blons H Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564 [TBL] [Abstract][Full Text] [Related]
10. Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma. Zhang C; Zhang J; Xu FP; Wang YG; Xie Z; Su J; Dong S; Nie Q; Shao Y; Zhou Q; Yang JJ; Yang XN; Zhang XC; Li Z; Wu YL; Zhong WZ J Thorac Oncol; 2019 Nov; 14(11):1912-1923. PubMed ID: 31446140 [TBL] [Abstract][Full Text] [Related]
11. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas. Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260 [TBL] [Abstract][Full Text] [Related]
12. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352 [TBL] [Abstract][Full Text] [Related]
13. The transcriptional landscape and mutational profile of lung adenocarcinoma. Seo JS; Ju YS; Lee WC; Shin JY; Lee JK; Bleazard T; Lee J; Jung YJ; Kim JO; Shin JY; Yu SB; Kim J; Lee ER; Kang CH; Park IK; Rhee H; Lee SH; Kim JI; Kang JH; Kim YT Genome Res; 2012 Nov; 22(11):2109-19. PubMed ID: 22975805 [TBL] [Abstract][Full Text] [Related]
14. Hot spot mutations in Finnish non-small cell lung cancers. Mäki-Nevala S; Sarhadi VK; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuuttila A; Knuutila S Lung Cancer; 2016 Sep; 99():102-10. PubMed ID: 27565922 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive Molecular Characterization of Young Chinese Patients with Lung Adenocarcinoma Identified a Distinctive Genetic Profile. Hou H; Zhu H; Zhao H; Yan W; Wang Y; Jiang M; Liu B; Liu D; Zhou N; Zhang C; Li P; Chang L; Guan Y; Wang Z; Zhang X; Li Z; Fang B; Zhang X Oncologist; 2018 Sep; 23(9):1008-1015. PubMed ID: 29700208 [TBL] [Abstract][Full Text] [Related]
16. Cancer genomics of lung cancer including malignant mesothelioma: A brief overview of current status and future prospects. Jhanwar SC; Xu XL; Elahi AH; Abramson DH Adv Biol Regul; 2020 Dec; 78():100723. PubMed ID: 32992231 [TBL] [Abstract][Full Text] [Related]
17. Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung Adenocarcinoma. Oezkan F; Herold T; Darwiche K; Eberhardt WEE; Worm K; Christoph DC; Wiesweg M; Freitag L; Schmid KW; Theegarten D; Hager T; Koenig MJ; He K; Taube C; Schuler M; Breitenbuecher F Clin Lung Cancer; 2018 Nov; 19(6):e879-e884. PubMed ID: 30206042 [TBL] [Abstract][Full Text] [Related]
18. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. Ruiz-Cordero R; Ma J; Khanna A; Lyons G; Rinsurongkawong W; Bassett R; Guo M; Routbort MJ; Zhang J; Skoulidis F; Heymach J; Roarty EB; Tang Z; Medeiros LJ; Patel KP; Luthra R; Roy-Chowdhuri S BMC Cancer; 2020 Jan; 20(1):83. PubMed ID: 32005111 [TBL] [Abstract][Full Text] [Related]
19. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689 [TBL] [Abstract][Full Text] [Related]
20. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients. Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]